BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y

Core Insights - Beam Therapeutics reported a narrower loss of 10 cents per share in Q4 2025, significantly better than the Zacks Consensus Estimate of a loss of $1.13 and an improvement from a loss of $1.09 per share in the same quarter last year [1][7] - The company achieved revenues of $114.1 million in Q4 2025, surpassing the Zacks Consensus Estimate of $15 million and showing a substantial increase from $30.1 million in the year-ago quarter [2][7] - For the full year 2025, Beam Therapeutics reported total revenues of $139.7 million, marking a 120% increase year over year [8] Financial Performance - Research and development expenses for Q4 were $99.3 million, down 2.1% from the previous year [3] - General and administrative expenses rose by 12.6% year over year to $32.3 million [3] - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $1.25 billion, an increase from $1.1 billion as of September 30, 2025 [3] Funding and Future Plans - Beam Therapeutics secured a $500 million non-dilutive senior credit facility from Sixth Street to support the potential launch of ristoglogene autogetemcel (risto-cel) for sickle cell disease, which includes a $100 million upfront payment and milestone-based funding [4][7] - The financing extends the company's cash runway into mid-2029 [4][7] - Beam plans to submit a biologics licensing application (BLA) for risto-cel by the end of 2026 [9] Pipeline Developments - The company is advancing its ex-vivo genome-editing candidate, risto-cel, in the phase I/II BEACON study for sickle cell disease [9] - Beam is also developing BEAM-301 and BEAM-302 for glycogen storage disease type 1a and alpha-1 antitrypsin deficiency, respectively, with initial data expected in 2026 [10][11] - Additionally, the company is expanding its pipeline with BEAM-304 for phenylketonuria, planning to file an investigational new drug application with the FDA in 2026 [12]